Charles River Laboratories has acquired Agilux Laboratories, Inc., a Worcester, MA-based CRO that provides discovery small and large molecule bioanalytical services, drug metabolism and pharmacokinetic (DMPK) services, and pharmacology services. Agilux was acquired from a holding company controlled by the company’s founders and sole investor, Ampersand Capital Partners.
 
The acquisition adds integrated discovery capabilities to Charles River’s nonclinical portfolio. Charles River believes the acquisition enhances its ability to work with clients earlier in the drug research process, and maintain the relationship as molecules progress through nonclinical development.
 
James C. Foster, chairman, president and chief executive officer of Charles River said, “The acquisition of Agilux Laboratories supports Charles River’s strategy to offer clients a broader, integrated portfolio that enables them to work with us continuously from the earliest stages of drug research through the nonclinical development process. Agilux reinforces the linkage between our discovery and safety assessment capabilities, and provides clients with a comprehensive testing solution that spans their discovery and regulated drug development needs. We expect to leverage Agilux’s strong client relationships in the Boston-Cambridge biohub, one of the most significant concentrations of medical research in the world, and expand the reach of its discovery bioanalytical services offering to Charles River’s global client base.”